KRAS and BRAF Concomitant Mutations in a Patient with Metastatic Colon Adenocarcinoma: An Interesting Case Report

• Main Authors: Concetta Cafiero, Agnese Re, Gerardo D’Amato, Pier Luigi Surico, Giammarco Surico, Michele Pirrelli, Salvatore Pisconti
• Format: Article
• Language: English
• Published: Karger Publishers 2020-06-01
• Series: Case Reports in Oncology
• Subjects: colorectal cancer; kras; braf; therapeutic responses
• Online Access: https://www.karger.com/Article/FullText/507882

A 68-year-old female patient with tenesmus and blood in the stool was admitted to the S.G. Moscati Hospital of Taranto. Investigations revealed infiltrative mucinous colon adenocarcinoma accompanied by lymph node metastases. Following surgery and adjuvant chemotherapy, computed tomography (CT) and carcinoembryonic antigen screening were negative. Two years later, CT demonstrated a liver lesion. Histologic and genetic analyses confirmed the diagnosis of metastatic colorectal cancer with the coexistence of KRAS and BRAF mutations in hepatic metastases and the presence of the BRAF V600E in the primary tumour. It is unclear whether the lack of response was due to BRAF mutations, but the data suggest that mutated BRAF confers resistance to anti-epidermal growth factor receptor therapy. In our patient, BRAF mutation turned out to be a negative prognostic factor, and it may have been the cause of clinical implications for disease progression and therapeutic responses.